Unknown

Dataset Information

0

A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation.


ABSTRACT: About 40% of the therapeutic agents in use today exert their effects through seven-transmembrane receptors (7TMRs). When activated by ligands, these receptors trigger two pathways that independently transduce signals to the cell: one through heterotrimeric GTP-binding proteins (G proteins) and one through beta-arrestins; so-called biased agonists can selectively activate these distinct pathways. Here, we investigate selective activation of these pathways through the use of a biased agonist for the type 1 parathyroid hormone (PTH)-PTH-related protein receptor (PTH1R), (D-Trp(12),Tyr(34))-PTH(7-34) (PTH-betaarr), which activates beta-arrestin but not classic G protein signaling. In mice, PTH-betaarr induces anabolic bone formation, as does the nonselective agonist PTH(1-34), which activates both mechanisms. In beta-arrestin2-null mice, the increase in bone mineral density evoked by PTH(1-34) is attenuated and that stimulated by PTH-betaarr is ablated. The beta-arrestin2-dependent pathway contributes primarily to trabecular bone formation and does not stimulate bone resorption. These results show that a biased agonist selective for the beta-arrestin pathway can elicit a response in vivo distinct from that elicited by nonselective agonists. Ligands with these properties may form the basis for improved 7TMR-directed pharmacologic agents with enhanced therapeutic specificity.

SUBMITTER: Gesty-Palmer D 

PROVIDER: S-EPMC2852200 | biostudies-literature | 2009 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation.

Gesty-Palmer Diane D   Flannery Pat P   Yuan Ling L   Corsino Leonor L   Spurney Robert R   Lefkowitz Robert J RJ   Luttrell Louis M LM  

Science translational medicine 20091001 1


About 40% of the therapeutic agents in use today exert their effects through seven-transmembrane receptors (7TMRs). When activated by ligands, these receptors trigger two pathways that independently transduce signals to the cell: one through heterotrimeric GTP-binding proteins (G proteins) and one through beta-arrestins; so-called biased agonists can selectively activate these distinct pathways. Here, we investigate selective activation of these pathways through the use of a biased agonist for t  ...[more]

Similar Datasets

| S-EPMC2943313 | biostudies-literature
| S-EPMC7502484 | biostudies-literature
| S-EPMC2672812 | biostudies-other
| S-EPMC6717746 | biostudies-literature
| S-EPMC150965 | biostudies-literature
| S-EPMC28367 | biostudies-literature
| S-EPMC3940307 | biostudies-literature
| S-EPMC7948418 | biostudies-literature
2020-02-18 | MSV000084971 | MassIVE
2021-01-17 | GSE145462 | GEO